MedTrace Logo

TCR-engineered T Cells in Solid Tumors: IMA202-101

NCT03441100 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-02-04

No results posted yet for this study

Summary

The study purpose is to establish the safety and tolerability of IMA202 product in patients with solid tumors that express melanoma-associated antigen 1 (MAGEA1).

Conditions

  • Solid Tumor, Adult
  • Refractory Cancer
  • Recurrent Cancer
  • Cancer

Interventions

DRUG

IMA202 Product

The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula.

DEVICE

IMADetect®

IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in clinical trials. IMADetect® is intended for investigational use only.

Sponsors & Collaborators

  • Immatics US, Inc.

    lead INDUSTRY

Principal Investigators

  • Cedrik Britten, MD · Immatics US, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-02
Primary Completion
2022-06-17
Completion
2023-03-17
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States
  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03441100 on ClinicalTrials.gov